Pentoxifylline inhibits perforin-dependent natural cytotoxicity in vitro

Oncology Reports

Volumn 9, Issue 2, 2002, Pages 423-426

  Lazarczyk, M ^a   Grzela, Tomasz ^a,b   Korczak Kowalska, G ^b   Niderla, J ^a   Oldak, M ^a   Jozwiak, J ^a   Skopinski, P ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Apoptosis; Cytotoxicity; Pentoxifylline; Perforin

Indexed keywords

ANTIINFLAMMATORY AGENT; CHROMIUM; DEXAMETHASONE; ENZYME INHIBITOR; MEMBRANE PROTEIN; MESSENGER RNA; PENTOXIFYLLINE; PERFORIN; PORE FORMING CYTOTOXIC PROTEIN;

ARTICLE; CELL CULTURE; CELL STRAIN K 562; CELL SURVIVAL; COMPARATIVE STUDY; DRUG EFFECT; ERYTHROLEUKEMIA; FLOW CYTOMETRY; GENETICS; HUMAN; IMMUNOLOGY; IN VITRO STUDY; METABOLISM; MONONUCLEAR CELL; SKIN TUMOR;

ANTI-INFLAMMATORY AGENTS; CELL SURVIVAL; CHROMIUM; DEXAMETHASONE; ENZYME INHIBITORS; FLOW CYTOMETRY; HUMANS; K562 CELLS; LEUKEMIA, ERYTHROBLASTIC, ACUTE; LEUKOCYTES, MONONUCLEAR; MEMBRANE GLYCOPROTEINS; PENTOXIFYLLINE; PORE FORMING CYTOTOXIC PROTEINS; RNA, MESSENGER; SKIN NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0036515611     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.9.2.423     Document Type: Article

References (30)

1. Mueller R: On the therapy of disturbances of blood fluidity. Angiology 1:226-234, 1985.
2. Aviado DM and Porter JM: Pentoxifylline: a new drug for the treatment of intermittent claudication. Mechanism of action, pharmacokinetics, clinical efficacy and adverse effects. Pharmacotherapy 4: 297-307, 1984. (Pubitemid 15181910)
3. Rieckmann P, Weber F, Gunther A, Martin S, Bitsch A, Broocks A, Kitze B, Weber T, Borner T and Poser S: Pentoxifylline, a phosphodiesterase inhibitor, induces immune deviation in patients with multiple sclerosis. J Neuroimmunol 64: 193-200, 1996. (Pubitemid 26096431)
4. Liang L, Beshay E and Prud'homme GJ: The phosphodiesterase inhibitors pentoxifylline and rolipram prevent diabetes in NOD mice. Diabetes 47: 570-575, 1998. (Pubitemid 28160447)
5. Tilg H, Eibl B, Pichl M, Gachter A, Herold M, Brankova J, Huber C and Niederwieser D: Immune response modulation by pentoxifylline in vitro. Transplantation 56: 196-201, 1993. (Pubitemid 23220598)
6. Lin Y, Goebels J, Rutgerts O, Kasran A, Van Gool S, Ceuppens J, Schonharting M and Waer M: Use of the methylxanthine derivative A802715 in transplantation immunology: I. Strong in vitro inhibitory effects on CD28-costimulated T cell activities. Transplantation 63: 1813-1818, 1997. (Pubitemid 27278957)
7. Funk JO, Ernst M, Schonharting M and Zabel P: Pentoxifylline exerts synergistic immunomodulatory effects in combination with dexamethasone or cyclosporine A. Int J Immunopharmaco 17: 1007-1016, 1995. (Pubitemid 26097583)
8. Reed WR and DeGowin RL: Suppressive effects of pentoxifylline on natural killer cell activity. J Lab Clin Med 119: 763-771, 1992.
9. Oshimi Y, Oshimi K and Miyazaki S: Necrosis and apoptosis associated with distinct Ca2+ response patterns in target cells attacked by human natural killer cells. J Physiol 495: 319-329, 1996. (Pubitemid 26331816)
10. Gardiner CM and Reen DJ: Differential cytokine regulation of natural killer cell-mediated necrotic and apoptotic cytotoxicity. Immunology 93: 511-517, 1998. (Pubitemid 28172623)
11. Giacomelli R, Passacantando A, Frieri G. Parzanese I, DAlo S, Vernia P, Pimpo MT, Petrucci C, Caprilli R, Cifone MG and Tonietti G: Circulating soluble factor-inhibiting natural killer (NK) activity of fresh peripheral blood mononuclear cells (PBMC) from inflammatory bowel disease (IBD) patients. Clin Exp Immunol 115: 72-77, 1999. (Pubitemid 29030365)
12. Brittenden J, Heys SD, Ross J and Eremin O: Natural killer cells and cancer. Cancer 77: 1226-1243, 1996. (Pubitemid 26102319)
13. Choe G, Lee Y, Hong W, Lee M and Jang J: Changes of host natural killer cell activity in F344 rats during gastric carcinogenesis induced by N-methylnitrosourea. Oncol Rep 6: 777-780, 1999.
14. Pross HF and Lotzova E: Role of natural killer cells in cancer. Nat Immun 12: 279-292, 1993. (Pubitemid 23297445)
15. Whiteside TL and Herberman RB: The role of natural killer cells in immune surveillance of cancer. Curr Opin Immunol 7: 704-710, 1995.
16. Derby E, Reddy V, Kopp W, Nelson E, Baseler N, Sayers T and Malyguine A: Three-color flow cytometric assay for the study of cell-mediated cytotoxicity. Immunol Lett 78: 35-39, 2001. (Pubitemid 32709904)
17. Aubry JP, Blaecke A, Lecoanet-Henchoz S, Jeannin P, Herbault N, Caron G, Moine V and Bonnefoy JY: Annexin V used for measuring apoptosis in the early events of cellular cytotoxicity. Cytometry 37: 197-204, 1999. (Pubitemid 29504086)
18. Elferink JG, Huizinga TW and de Koster BM: The effect of pentoxifylline on human neutrophil migration: a possible role for cyclic nucleotides. Bioch Pharm 54: 475-480, 1997. (Pubitemid 27376158)
19. Rossignol L, Plantavid M, Chap H and Douste-Blazy L: Effects of two methylxanthines, pentoxifylline and propentofylline, on arachidonic acid metabolism in platelets stimulated bythrombin. Bioch Pharm 37: 3229-3236, 1988.
20. Wang W, Tarn WF, Hughes CCW, Rath S and Sen R: C-Rel is a target of pentoxifylline-mediated inhibition of T lymphocyte activation. Immunity 6: 165-174, 1997. (Pubitemid 27145561)
21. Currie MS, Rao KM, Padmanabhan I, Jones A, Crawford J and Cohen HJ: Stimulus-specific effects of pentoxifylline on neutrophil CR3 expression, degranulation, and superoxide production. J Leucocyt Biol 47: 244-250, 1990. (Pubitemid 20097663)
22. Neuner P, Klosner G, Schauer G, Pourmojib M, Macheiner W, Grunwald C, Knobler R, Schwarz A, Luger TA and Schwarz T: Pentoxifylline in vivo down-regulates the release of IL-1 beta, IL-6, IL-8 and tumour necrosis factor-alpha by human peripheral blood mononuclear cells. Immunology 83: 262-267, 1994. (Pubitemid 24315597)
23. Rieneck K, Diamant M, Haahr PM, Schonharting M and Bendtzen K: In vitro immunomodulatory effects of pentoxifylline. Immunol Lett 37: 131-138, 1993. (Pubitemid 23303726)
24. Hari P and Srivastava RN: Pulse corticosteroid therapy with methylprednisolone or dexamethasone. Indian J Pediatr 65: 557-560, 1998. (Pubitemid 28387886)
25. Wirnsberger GH, Ratschek M, Dimai HP, Holzer H and Mandal AK: Post-transplantation lymphoproliferative disorder of the T-cell/B-cell type: an unusual manifestation in a renal allograft. Oncol Rep 6: 29-32, 1999. (Pubitemid 128532793)
26. Germing U, Kobbe G, Sohngen D, Motherby H, Braunstein S, Hey 11 A and Aul C: Early occurrence of an adenocarcinoma after allogeneic bone marrow transplantation in a patient with AML. Oncol Rep 6: 855-877, 1999.
27. De Bosscher K, Schmitz ML, Vanden Berghe W, Plaisance S, Fiers W and Haegeman G: Glucocorticoid-mediated repression of nuclear factor-kappaB- dependent transcription involves direct interference with transactivation. Proc Natl Acad Sei USA 94: 13504-13509, 1997. (Pubitemid 28009612)
28. Nagy Z, Spika R, Ocsovszki I, Balogh A and Mandi Y: Suppressive effect of pentoxifylline on natural killer cell activity: experimental and clinical studies. Naunyn Schmiedebergs Arch Pharmaco 359: 228-234, 1999. (Pubitemid 29142874)
29. Dormandy J, Heeck L and Vig S: Predictors of early disease in the lower limbs. Semin Vasc Surg 12: 109-117, 1999. (Pubitemid 29259198)
30. Mor V: Malignant disease and the elderly. Ciba Found Symp 134: 160-176, 1988.